TITLE

ROCHE SELECTS TWO GENMAB ANTIBODIES AS CLINICAL CANDIDATES

PUB. DATE
May 2004
SOURCE
Worldwide Biotech;May2004, Vol. 16 Issue 5, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the decision of Roche to select Genmab antibodies as candidates for clinical development. Terms of agreement between Roche and Ganmab AS; Value of Genmab and Roche collaboration; Background of Genmab.
ACCESSION #
13040744

 

Related Articles

  • Roche chooses to develop Genmab antibodies.  // PharmaWatch: Biotechnology;May 2004, Vol. 3 Issue 5, p8 

    Focuses on the selection of two Genmab AS antibodies by Roche as candidates for clinical development. Terms of the agreement; Production of antibody product candidates; Effectivity of the development of antibodies.

  • Breast Cancer Update.  // PharmaWatch: Cancer;Dec2006, Vol. 5 Issue 12, p9 

    No abstract available.

  • ROCHE/GLYCART TO DISCOVER NEW THERAPEUTIC ANTIBODIES.  // Worldwide Biotech;Nov2004, Vol. 16 Issue 11, p5 

    Reports on the agreement between Roche and GLYCART to discover next-generation therapeutic antibodies using GlycoMabTM technology. Terms of the agreement; Factors that influenced Roche to license GlycoMabTM; Profile of GLYCART and Roche; Information on GlycoMab.

  • Adimab Yeast-Based Platform Draws Big Pharma's Attention. Hollingsworth, Catherine // BioWorld Today;6/22/2009, Vol. 20 Issue 118, p1 

    This article reveals that Adimab Inc. has successfully secured two major drug discovery deals in June 2009. In addition, the company is involved in negotiations with several major drugmakers for possible collaborations in the future. Particular focus is gievn to the company's business model....

  • Biotechnology.  // PharmaWatch: Monthly Review;May 2004, Vol. 3 Issue 5, p44 

    Reports global developments on biotechnology as of March 15, 2004. Purchasing deal between Amgen Inc. and Tularik Inc.; Partnership between Genmab AS and Roche Pharmaceuticals company; Research and discovery collaboration agreement between NeoGenesis Pharmaceuticals Inc. and AstraZeneca PLC.

  • Biotechnology News Round-up.  // PharmaWatch: Biotechnology;May 2004, Vol. 3 Issue 5, p2 

    Reports global developments related to biotechnology as of May 2004. Acquisition of Tularik Inc. by Amgen Inc.; Consolidation of Genmab AS and Roche; Collaboration agreement between NeoGenesis Pharmaceuticals Inc. and AstraZeneca PLC.

  • Genentech's Avastin receives positive European opinion for colorectal cancer.  // PharmaWatch: Cancer;December2004, Vol. 3 Issue 12, p9 

    Reports that Roche Inc.'s and Genentech Inc.'s co-developed innovative cancer drug, Avastin, has received a positive recommendation from the European Committee for Medicinal Products for Human Use (CHMP). Recommendation of CHMP that Avastin in combination with other drugs be indicated as...

  • Roche: MabThera maintains its momentum.  // PharmaWatch: Cancer;Dec2005, Vol. 4 Issue 12, p13 

    The article presents information about Roche Holding AG's anti-cancer drug MabThera. Clinical trials of the drug has shown positive results in the treatment of non-Hodgkin's lymphoma. Experts believe that MabThera maintenance therapy could become the new standard treatment in non-Hodgkin's...

  • Roche: MabThera maintains its momentum.  // PharmaWatch: Monthly Review;Dec2005, Vol. 4 Issue 12, p10 

    The article informs that drug manufacturer Roche Pharmaceuticals has reported positive results from a phase III study evaluating MabThera as maintenance treatment in non-Hodgkin's lymphoma. The findings will support an application to extend the product's European label, and could lead US...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics